Author Intervention Participants prescribed a gabapentinoid Comparator Outcomes Time-points
McDonald 2022 The provision of individualised deprescribing reports supplied within 3 business days of patient admission, based on evidence-based guidelines for safer prescribing in older adults, with tapering instructions when indicated, generated by MedSafer software. Gabapentinoids were listed as a “potentially inappropriate medication”. 925 participants of which 729 were identified to have potentially been inappropriately prescribed Usual care (best-possible medication history performed) Dose cessation or reduction, ADEs and SAEs, QoL Short-term
Kasper 2014
A 24-wk placebo- and lorazepam-controlled, randomized, double-blind, multicentre trial. Period 1 contained a 6-week fixed dose of either high dose pregabalin (450-600mg/day), low dose pregabalin (150-300 mg/day), or lorazepam. Responders continued for another 6 weeks. Then, in the double-blind period 2, 25% of patients from each medication group were randomised to discontinue the active medication by receiving a matching placebo. 206 participant per group underwent 12 weeks of high or low dose pregabalin (Period 1), then randomised to: Maintain low dose (n =112) versus placebo (n = 39) OR Maintain high dose (n = 121) versus placebo (n = 38)]
Placebo
Does cessation, ADEs, including ADWEs, SAEs, QoL
Intermediate-term
Chazot 2021a
Clinicians received GOTT (Gabapentinoids and Opioids Tapering Tool Box), to improve confidence of clinicians and patients to self-manage pain with safe prescribing. 10 Footsteps programme to achieve this goal was developed to increase the motivation: (a) for health care professionals to listen to patients,
(b) patients to understand their pain and engage with strategies that help their long-term management,
(c) create communities that are sufficiently socially resilient to allow that to happen (Ten Footsteps - Live Well With Pain).
Not reported
Nil
Reduction in prescribing rates
Intermediate-term
Collinson 2019a Chart review of patients in May 2018 to determine baseline prescribing of gabapentinoids (n = 144 patients), plus a review of prescription charts of a randomised sample (n = 30) were accessed to ascertain whether indications were listed by the British National Formulary. Airedale Clinical Commissioning Group reported that 2% of patients registered at Haworth Medical Practice were taking gabapentinoids. 30 participants randomly chosen out of the 144 patients prescribed a gabapentinoid in May 2018 Nil Reduction in prescribing rates Intermediate-term